{"meshTags":["Adult","Antineoplastic Agents","Benzamides","Chemotherapy, Adjuvant","Combined Modality Therapy","Gastrointestinal Stromal Tumors","Humans","Ileal Neoplasms","Imatinib Mesylate","Jejunal Neoplasms","Male","Middle Aged","Neoplasm Recurrence, Local","Piperazines","Pyrimidines","Tomography, X-Ray Computed","Treatment Outcome"],"meshMinor":["Adult","Antineoplastic Agents","Benzamides","Chemotherapy, Adjuvant","Combined Modality Therapy","Gastrointestinal Stromal Tumors","Humans","Ileal Neoplasms","Imatinib Mesylate","Jejunal Neoplasms","Male","Middle Aged","Neoplasm Recurrence, Local","Piperazines","Pyrimidines","Tomography, X-Ray Computed","Treatment Outcome"],"genes":["tyrosine kinase","c-kit"],"organisms":["9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Imatinib, an inhibitor of the tyrosine kinase activity of c-kit, was used as an adjuvant chemotherapy in two patients who underwent curative surgery for recurrent gastrointestinal stromal tumors. One patient has maintained tumor-free survival for 12 months, while the other had rapid recurrence and metastasis of tumors 3 months after he discontinued the drug. The indication and effects of imatinib for prevention of recurrence of GIST after ablative surgery were discussed.","title":"Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.","pubmedId":"15966213"}